
Work Here?
Rimsys offers a SaaS platform for medtech regulatory affairs. It centralizes regulatory information and automates processes across clinical, product, and quality systems, with automated alerts and digital maintenance of essential regulatory tables. It differentiates itself through strong integration with a company’s existing tools, continuous regulatory updates, and optional consulting to reduce administrative work and risk. Its goal is to help global medtech players stay compliant with regulations like EU MDR and IVDR while managing regulatory complexity in a cost-effective way.
Industries
Data & Analytics
Enterprise Software
Healthcare
Company Size
11-50
Company Stage
Debt Financing
Total Funding
$32M
Headquarters
Pittsburgh, Pennsylvania
Founded
2017
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$32M
Above
Industry Average
Funded Over
7 Rounds
Rimsys announces ai-native Market Access for regulated products. * Business Wire * Sep 1, 2026 PITTSBURGH-(BUSINESS WIRE)-Sep 1, 2026- Rimsys, the heart of medtech regulatory operations, today announced Market Access, a new AI-native product designed to help companies determine whether a market is worth entering and what it will take to get there. Market Access will be available in beta beginning September 1, 2026, with general availability to be announced separately. From market-entry decision to regulatory execution. AI-native Market Access helps medtech teams decide whether, when, and how to enter a market, then connects the plan to AI-enabled RIM for execution. Market Access replaces what can be a 6-to-9-month research and assessment process with a same-day, actionable read on market viability. It gives regulatory and commercial leaders the classification, pathway, timeline, cost considerations, and potential regulatory gaps they need to make a more defensible investment decision before committing budget and resources. Predictability is at the core of Market Access. Rather than simply identifying a regulatory pathway, it helps teams understand what to expect, which requirements or gaps are most likely to slow down a submission, and where uncertainty remains. Every answer traces back to the specific regulation, guidance, or law behind it, allowing regulatory professionals to verify the underlying source rather than simply trust an AI-generated response. Key features and benefits include: * Same-day market assessment: Provides an actionable read on whether a market is worth entering, replacing research and assessment that can take 6 to 9 months. * Cross-designation classification: Evaluates products across medical device, IVD, cosmetic, consumer, and OTC designations, so the same product receives the appropriate regulatory read regardless of how a given market classifies it. * Clear market-entry requirements: Provides classification, regulatory pathway, timeline, cost considerations, and key requirements before teams commit resources. * Earlier visibility into regulatory gaps: Surfaces the specific requirements and gaps most likely to slow down a submission and helps teams understand their potential severity. * Greater predictability: Provides visibility into anticipated regulatory response windows, risks, and areas of uncertainty so teams can better plan for what lies ahead. * Source-linked intelligence: Traces answers to the underlying regulations, guidance, and laws so regulatory professionals can verify the basis for an assessment. * AI with human oversight: Uses Rimsys AI and Market Manager Agents to accelerate complex regulatory research while keeping regulatory professionals in control of review and validation. * Connected planning and execution: Complements RIM, connecting market-entry decisions with the registrations, submissions, regulatory changes, and ongoing compliance required to execute them. "Regulatory knowledge has traditionally been highly dependent on individual expertise and market-by-market research," said James Gianoutsos, Founder and CEO of Rimsys. "Market Access gives companies greater predictability before they make a market investment. Teams can understand whether an opportunity is worth pursuing, what it will take to enter, where regulatory challenges are likely to emerge, and what uncertainty remains. And because every answer is tied to its regulatory source, experts can verify the recommendation rather than simply trust the AI." Market Access is powered by Rimsys AI, which works from a curated regulatory corpus spanning more than 200 markets, not the open web. Its Market Manager Agents are AI agents with market-specific regulatory knowledge, including pathways, requirements, and documentation, that support market assessments and global launch planning. The product is also designed to acknowledge areas where reviewer interpretation and expert judgment can affect regulatory outcomes rather than presenting those outcomes as more predictable than they are. Market Access expands the Rimsys product portfolio from regulatory execution into market planning. Market Access helps regulatory and commercial leaders determine where to compete, while RIM manages the registrations, submissions, regulatory changes, product data, and ongoing compliance required to enter and remain in those markets. Together, they turn regulatory intelligence into coordinated action, helping regulatory teams accomplish more in every hour while giving business leaders greater visibility into opportunities, risk, and the work required to protect and grow revenue. Beta Availability Market Access will be available in beta beginning September 1, 2026. During the beta period, Rimsys will continue validating product capabilities and refining workflows ahead of broader commercial availability. Organizations interested in learning more about Market Access or participating in the beta program can visit rimsys.io/products/market-access. About Rimsys Rimsys is the heart of regulatory operations, connecting AI-native market planning with AI-embedded regulatory execution, giving medtech manufacturers one living system from market-entry decision to execution. Rimsys Market Access is the planning layer, answering not just whether a market can be entered, but whether it should be, returning classification, pathway, timeline, and cost before a team commits budget or resources to finding out. Rimsys RIM is the execution layer, managing registrations, submissions, regulatory changes, and compliance so teams can act on that plan with confidence. Trusted by 6 of the top 12 global MedTech manufacturers and certified to ISO 27001 and SOC 2, with ISO 42001 certification for AI management systems underway, Rimsys keeps regulatory intelligence, product data, approvals, and change management continuously connected so teams can enter new markets with speed and assurance. Learn more at rimsys.io. KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: TECHNOLOGY MOBILE/WIRELESS HEALTH OTHER HEALTH ARTIFICIAL INTELLIGENCE OTHER TECHNOLOGY PRACTICE MANAGEMENT SOFTWARE MANAGED CARE NETWORKS GENERAL HEALTH HOSPITALS HEALTH TECHNOLOGY DATA MANAGEMENT PUB: 09/01/2026 07:15 AM/DISC: 09/01/2026 07:16 AM
Rimsys, a regulatory information management software provider for medical technology, has launched its Spring 2026 release, introducing a "Regulatory Execution Engine" that moves beyond data storage to active execution. The platform includes Rimsys Intelligence, which uses AI to monitor regulatory changes across over 90 countries, and Advanced Submissions, featuring native word-compatible authoring that eliminates the need to switch between platforms. The Rimsys Editor enables real-time co-authoring and AI-assisted content creation. Universal Submissions allows teams to build from a single template and adapt it for multiple markets, whilst Reusable Submissions can reduce content creation time by up to 90%. The company serves 6 of the top 12 global medical technology manufacturers. The platform aims to accelerate market access and reduce submission cycle times.
Rimsys Launches the Regulatory Execution Engine for MedTech. Spring 2026 embeds submission authoring, AI-powered regulatory monitoring, and configurable impact workflows inside a single RIM platform, the first step toward Rimsys' AI vision for global regulatory operations. PITTSBURGH-(BUSINESS WIRE)-Regulatory Information Management (RIM) software was built to store records. That foundation has served its purpose and reached its limit. Today, Rimsys announces the Spring 2026 release: a platform designed not to hold regulatory data, but to execute on it. "Our vision for Rimsys is a platform that makes regulatory expertise go further, companies move faster, and products reach more markets than any team could accomplish alone. Spring 2026 is another meaningful step toward that vision." Share Submission volumes are growing. Markets are multiplying. Regulatory change is accelerating. Spring 2026 gives regulatory teams the tools to keep pace: embedded authoring, reusable submission content, configurable impact workflows, and AI-powered intelligence, all inside a single platform. "Our vision for Rimsys is a platform that makes regulatory expertise go further, companies move faster, and products reach more markets than any team could accomplish alone. Spring 2026 is another meaningful step toward that vision. We are embedding the tools and intelligence that allow regulatory affairs professionals to operate at a different level, doing more strategic work, entering markets faster, and staying ahead of regulatory change rather than reacting to it. What we are building next makes this release the starting line." - James Gianoutsos, CEO What Spring 2026 Delivers A brand new website that provides in-depth information about the Rimsys offering and the benefits to MedTech manufacturers, including details on these new products: Intelligence: AI-Powered Regulatory Monitoring Rimsys Intelligence provides access to regulations, guidance documents, safety alerts, and legislation across more than 90 countries. AI triage and prioritization surface the updates most relevant to each customer's specific products and markets, eliminating hours of manual surveillance and putting the right information in front of the right people. When a change requires action, teams can move directly from regulatory signal to impact assessment without a manual handoff. Intelligence represents Rimsys' first production deployment of context-aware AI operating across a customer's live regulatory data, a foundation that will expand significantly in future releases. Advanced Submissions: A Unified Submission Execution Workflow Advanced Submissions consolidates everything required to create, manage, and publish a regulatory submission into a single workflow inside Rimsys, eliminating the disconnected tools, manual reformatting, and version fragmentation that have defined submission work for too long. Three capabilities anchor it: Rimsys Editor The Rimsys Editor is the cornerstone of Advanced Submissions and the most significant capability in this release. It brings word-compatible authoring and editing natively inside Rimsys, fully compatible with Microsoft Word(R), allowing regulatory teams to create, co-author, review, and publish submission content without leaving the platform for the first time. The Editor supports real-time co-authoring, tracked changes and redlining, rich content including tables and images, document comparison, and PDF publishing with standardized headers, footers, and company branding applied automatically. AI-assisted authoring is available as a configurable option, enabling teams to summarize, refine, expand, and translate content within their workflow. Rimsys AI is human-in-the-loop by design. Universal Submissions Universal Submissions enables teams to build from a single universal template (an IMDRF Technical Document) with content automatically mapped into market-specific templates. One master structure, many markets, without rebuilding from scratch. Reusable Submissions Reusable Submissions takes a completed submission from one market and uses it as the starting point for a new one. The system automatically maps content into the target market's template, carrying applicable sections forward reducing the content creation time up to 90% and compressing the time required to enter each additional market. Configurable Impact Surveys: Governed Change Assessment at Scale Impact Surveys are now fully configurable. Templates can be defined for specific change event types, tied to countries or registrations, and triggered automatically from Rimsys Intelligence findings replacing ad hoc assessments with repeatable, governed workflows. This integration creates a direct line from change event to regulatory scope, with results tracked in a single audit-ready trail. A Platform Built for What's Next Spring 2026 establishes more than a set of new capabilities. It establishes the execution infrastructure, structured data model, and embedded AI foundation on which Rimsys' longer-term vision is being built. That vision: a world where regulatory experts are amplified by intelligence, not constrained by information. Where the knowledge required to enter a new market, interpret a regulatory change, or scope a submission is instantly available to every member of the team. Where regulatory operations scale not by spreading experts thin, but by giving them tools that multiply their impact. Spring is the first production step in that direction. Every submission authored inside the platform, every intelligence signal triaged by AI, and every impact assessment connected to structured regulatory data deepens the foundation. Future releases will build on it directly, expanding AI capabilities, automating more of the regulatory workflow, and ultimately enabling teams to do work that today requires external expertise to be done inside Rimsys. Regulatory Execution as a Business Lever Spring 2026 is built to move metrics that matter: reduced submission cycle time variance, improved approval predictability, lower marginal effort per market, and increased team capacity without proportional headcount growth. For executive leadership, earlier approvals translate directly into faster market access and accelerated revenue recognition. Availability Spring 2026 is now Generally Available. Existing customers on the Organizer product will retain access to their current experience. To learn more about the Spring 2026 release and how Rimsys can accelerate your regulatory operations, visit rimsys.io or contact your Rimsys representative. About Rimsys Rimsys is the heart of regulatory operations for the medical device industry and the platform at the center of an AI-driven transformation in how regulated products reach global markets. A living, connected regulatory platform, Rimsys keeps regulatory intelligence, product data, approvals, and change management continuously connected, enabling organizations to expand into global markets with speed, precision, and confidence. Enterprise-ready yet intuitive to use, Rimsys is trusted by 6 of the top 12 global MedTech manufacturers to accelerate time to market and scale regulatory operations worldwide. To learn more, visit rimsys.io. More News From Rimsys PITTSBURGH-( BUSINESS WIRE )-Rimsys, the global leader in Regulatory Information Management (RIM) software for the MedTech industry, today announced two major enhancements to its platform: expanded Unique Device Identification (UDI) capabilities to support EUDAMED machine-to-machine (M2M) bulk transmission and Rimsys Connect(TM), a new enterprise Change Data Capture (CDC) solution that provides near real-time synchronization of Rimsys data with customers' Business Intelligence (BI) solutions. Toge... PITTSBURGH-( BUSINESS WIRE )-Rimsys, the global leader of MedTech Regulatory Information Management (RIM) software, today announced that it has entered into a strategic alliance relationship with KPMG to advance digital transformation in the MedTech industry. "KPMG's deep experience in advisory and business transformation services and exceptional reputation make them a valuable alliance relationship for us," said James Gianoutsos, Founder and CEO of Rimsys. "KPMG is on the cutting edge of indus... BERLIN-( BUSINESS WIRE )-Rimsys announced today the beta launch of its free, centralized global regulatory intelligence hub for the medtech community, Rimsys Intel... Rimsys. Headquarters: Pittsburgh, PA CEO: James Gianoutsos Employees: 50 Organization: PRI Release Summary Rimsys Launches the Regulatory Execution Engine for MedTech: Spring 2026 is the first step toward Rimsys' AI vision for global regulatory operations. Release Versions
Rimsys enters strategic alliance relationship with KPMG.
Rimsys, developer of a cloud-based regulatory software designed to help medical device companies actively track the regulatory landscape, raised $5.3 million through a combination of Series AA-1, and Series AA venture funding from Riverfront Ventures, Innovation Works and GO Philly Fund putting the company's pre-money valuation at $21 million.
Find jobs on Simplify and start your career today
Industries
Data & Analytics
Enterprise Software
Healthcare
Company Size
11-50
Company Stage
Debt Financing
Total Funding
$32M
Headquarters
Pittsburgh, Pennsylvania
Founded
2017
Find jobs on Simplify and start your career today